<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id><journal-title-group><journal-title>Investigational New Drugs</journal-title></journal-title-group><issn pub-type="ppub">0167-6997</issn><issn pub-type="epub">1573-0646</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26189513</article-id><article-id pub-id-type="pmc">4768212</article-id><article-id pub-id-type="publisher-id">272</article-id><article-id pub-id-type="doi">10.1007/s10637-015-0272-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Phase I Studies</subject></subj-group></article-categories><title-group><article-title>Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gustavsson</surname><given-names>Bengt</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Carlsson</surname><given-names>G&#x000f6;ran</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Swartling</surname><given-names>Torbj&#x000f6;rn</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kurlberg</surname><given-names>G&#x000f6;ran</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Derwinger</surname><given-names>Kristoffer</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Bj&#x000f6;rkqvist</surname><given-names>Hillevi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Odin</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gibson</surname><given-names>Fernando</given-names></name><address><phone>+44 203 675 7065</phone><email>fernando.gibson@pharmagenesis.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Surgery, University of Gothenburg, Sahlgrenska University Hospital/&#x000d6;stra Institute of Clinical Sciences, Gothenburg, Sweden </aff><aff id="Aff2"><label/>PharmaGenesis London, 9 Whitehall, 4th Floor, London, SW1A 2DD UK </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>33</volume><fpage>1078</fpage><lpage>1085</lpage><history><date date-type="received"><day>25</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><title>Summary</title><p><italic>Background</italic> Modufolin&#x000ae; ([6R]-5,10-methylene tetrahydrofolate; [6R]-MTHF) is an endogenous biomodulator that is being developed as an alternative to leucovorin, a folate prodrug used in the treatment of colorectal cancer. The objective of this phase 1 dose de-escalation trial was to estimate the minimum tolerated dose of [6R]-MTHF to be used in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup> in the neoadjuvant treatment of patients with rectal cancer. <italic>Methods</italic> Adult patients (&#x02265;18&#x000a0;years) with resectable rectal adenocarcinoma were allocated to [6R]-MTHF doses of 500, 100, 50, and 10&#x000a0;mg/m<sup>2</sup> in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup>. [6R]-MTHF was administered as an intravenous (i.v.) bolus injection 1&#x000a0;week prior to the first dose of pemetrexed and then once weekly for 9&#x000a0;weeks; pemetrexed was administered by i.v. infusion once every 21&#x000a0;days for three cycles. <italic>Results</italic> Twenty-four patients (mean [SD] age, 63.1 [12.9] years) were enrolled in the study. A total of 72 treatment-related adverse events (AEs) were reported, of which the most common were fatigue (<italic>n</italic>&#x02009;=&#x02009;17; 23.6&#x000a0;%), nausea (<italic>n</italic>&#x02009;=&#x02009;10; 13.9&#x000a0;%), and diarrhea (<italic>n</italic>&#x02009;=&#x02009;5; 6.9&#x000a0;%). The incidence of treatment-related AEs by [6R]-MTHF dose level (500, 100, 50, 10&#x000a0;mg/m<sup>2</sup>) was 11.1&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;8), 13.9&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;10), 45.8&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;33), and 29.2&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;21), respectively. There were no dose-limiting toxicities, and only two (2.8&#x000a0;%) treatment-related AEs were grade 3 in severity. Of the 11 serious AEs reported, none were considered to be related to [6R]-MTHF treatment. <italic>Conclusions</italic> The results of this phase 1 study indicate that the estimated minimum tolerated dose of [6R]-MTHF was 100&#x000a0;mg/m<sup>2</sup> once weekly in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup>. The low toxicity profile of [6R]-MTHF supports its further evaluation as a component of systemic chemotherapy in the management of colon and rectal cancer.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s10637-015-0272-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>[6R]-5,10-methylene tetrahydrofolate</kwd><kwd>Endogenous folate</kwd><kwd>Antifolates</kwd><kwd>Phase 1 trial</kwd><kwd>Pemetrexed</kwd><kwd>Neoadjuvant therapy</kwd><kwd>Rectal cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media New York 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>The GLOBOCAN 2012 report ranks colorectal cancer as the third most commonly diagnosed cancer (1.36 million cases, 9.7&#x000a0;%) after lung and breast cancer, and the fourth highest cause of cancer death (694,000 deaths) behind lung, liver, and stomach cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. In the USA, rectal cancer accounts for approximately 25&#x000a0;% of colorectal cancer cases [<xref ref-type="bibr" rid="CR2">2</xref>], whereas across Europe, the reported proportion of rectal cancer cases is variable, ranging from 27 to 58&#x000a0;% [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>In patients with early (T1 or T2) rectal cancers involving less than 40&#x000a0;% of the circumference and without lymphovascular invasion, curative resection is a viable and effective therapeutic option [<xref ref-type="bibr" rid="CR4">4</xref>]. However, for patients with locally advanced (T3 or T4) rectal cancer, the classical treatment approach consists of combined modality therapy, comprising radiation and chemotherapy in the adjuvant (postoperative) setting [<xref ref-type="bibr" rid="CR5">5</xref>]. This algorithm was adopted in the 1990s, based on seminal studies which showed that adjuvant chemotherapy based on 5-fluorouracil (5-FU), radiation, or combined chemoradiotherapy (CRT) significantly decreased the rates of local recurrence in patients with locally advanced rectal cancer when compared with resection alone [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>The introduction of total mesorectal excision (TME) reduced the local recurrence rate to approximately 10&#x000a0;%, equivalent to that achieved with conventional surgery with adjuvant CRT [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. These findings raised questions regarding the need for adjuvant CRT and whether neoadjuvant CRT might be superior to adjuvant CRT in improving patient outcomes. Although there is no overall or disease-free survival benefit for neoadjuvant compared with adjuvant CRT [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], multiple phase 3 studies have demonstrated that neoadjuvant fluoropyrimidine-based CRT decreases local recurrence rates, induces tumor downstaging, improves the odds of anal sphincter preservation, and increases response rates compared with adjuvant CRT [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. These findings led to the adoption of neoadjuvant CRT followed by TME and adjuvant chemotherapy as the current standard of care for the treatment of locally advanced rectal cancer [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Despite the improved local control with neoadjuvant CRT, approximately a third of patients develop distant metastases [<xref ref-type="bibr" rid="CR24">24</xref>]. With this in mind, strenuous efforts have been made to investigate various combinations and dosing schedules of chemotherapeutic agents with the aim of improving the safety and efficacy of neoadjuvant CRT [<xref ref-type="bibr" rid="CR25">25</xref>]. The reduced folate leucovorin (5-formyl tetrahydrofolate) potentiates the cytotoxic activity of 5-FU, an inhibitor of thymidylate synthase [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], and is an important component of fluoropyrimidine-based chemotherapy in the treatment of colorectal cancer [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. However, leucovorin is a prodrug that requires metabolic conversion to the active cofactor [6R]-5,10-methylene tetrahydrofolate ([6R]-MTHF; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). In the presence of 5-FU, MTHF forms a stable, ternary complex with 5-fluorodeoxyuridine monophosphate and thymidylate synthase, thereby inhibiting thymidylate synthase activity [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. MTHF levels have been shown to be among the lowest of the reduced folates in tumor cells following leucovorin administration [<xref ref-type="bibr" rid="CR36">36</xref>], suggesting the hypothesis that the direct administration of MTHF might provide superior antitumor activity to that of leucovorin, particularly in patients who convert leucovorin to MTHF at a slow rate or catabolize leucovorin rapidly. Preclinical data in support of this idea was provided by Carlsson et al. [<xref ref-type="bibr" rid="CR37">37</xref>], who found that the administration of 5-FU in combination with MTHF completely eliminated tumor take in rats inoculated with colon adenocarcinoma cells.<fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of folate metabolism. <italic>Abbreviations: DHF</italic> dihydrofolate, <italic>DHFR</italic> dihydrofolate reductase, <italic>dTMP</italic> deoxythymidine monophosphate, <italic>dUMP</italic> deoxyuridine monophosphate, <italic>MTHFD</italic> methylene tetrahydrofolate dehydrogenase, <italic>MTHFR</italic> methylene tetrahydrofolate reductase, <italic>MTHFS</italic> methylene tetrahydrofolate synthase, <italic>SHMT1</italic> serine hydroxymethyl transferase 1, <italic>THF</italic> tetrahydrofolate, <italic>TS</italic> thymidylate synthase</p></caption><graphic xlink:href="10637_2015_272_Fig1_HTML" id="MO1"/></fig></p><p>Pemetrexed is a folate analogue that inhibits several folate-dependent enzymes in addition to thymidylate synthase, and was therefore thought to have theoretical advantages over fluoropyrimidines in the treatment of colorectal cancer [<xref ref-type="bibr" rid="CR38">38</xref>]. Underhill et al. [<xref ref-type="bibr" rid="CR39">39</xref>] reported the results of a randomized phase 2 trial of pemetrexed plus irinotecan (ALIRI) versus 5-FU plus leucovorin plus irinotecan (FOLFIRI) in patients with advanced or metastatic colorectal cancer. Progression-free survival in the ALIRI arm was significantly shorter than in the FOLFIRI arm (ALIRI, 5.7&#x000a0;months; FOLFIRI, 7.7&#x000a0;months; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), and the number of drug-related deaths was higher (ALIRI, 4; FOLFIRI, 1), indicating that pemetrexed is not superior to 5-FU-based therapy in the treatment of metastatic colorectal cancer, in terms of either efficacy or safety. However, a phase 1/2 feasibility trial of preoperative pemetrexed therapy in patients with resectable rectal cancer showed a significant reduction of tumor size (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and tumor-related symptoms (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.018), with a low incidence (10.8&#x000a0;%) of grade 3 or 4 adverse effects [<xref ref-type="bibr" rid="CR40">40</xref>], indicating that pemetrexed is a promising treatment option in the neoadjuvant setting.</p><p>Modufolin&#x000ae; (Isofol Medical AB, Gothenburg, Sweden) is a pure, stable formulation of the [6R]-diastereoisomer of MTHF that was developed as an alternative to leucovorin for the treatment of colon and rectal cancer [<xref ref-type="bibr" rid="CR41">41</xref>]. Wettergren et al. [<xref ref-type="bibr" rid="CR42">42</xref>] recently reported the results of a comparative pharmacokinetic/pharmacodynamic study of [6R]-MTHF and leucovorin in patients with colon cancer. The administration of [6R]-MTHF resulted in significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) higher concentrations of MTHF in mucosa and tumors than were seen following leucovorin administration.</p><p>The objective of this phase 1 dose de-escalation trial was to estimate the minimum tolerated dose of [6R]-MTHF to be used in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup> in the neoadjuvant treatment of patients with resectable rectal cancer.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients</title><p>Adult patients (&#x02265;18&#x000a0;years of age) with histologically confirmed, resectable adenocarcinoma of the rectum were eligible for inclusion in this single-center, phase 1, open-label, dose de-escalation trial (ISO-MC-091; ClinicalTrials.gov: NCT01397305; EudraCT 2009-009999-12A). The study was conducted between 14 April 2011 and 16 May 2014. Patients were required to have adequate hematologic function (hemoglobin &#x02265;9&#x000a0;g/L, neutrophils &#x02265;1.5&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L, platelet count &#x02265;100&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L), hepatobiliary function (serum bilirubin &#x0003c;1.5&#x02009;&#x000d7;&#x02009;upper limit of normal range [ULNR], alkaline phosphatase &#x0003c;3&#x02009;&#x000d7;&#x02009;ULNR, aspartate aminotransferase &#x0003c;3&#x02009;&#x000d7;&#x02009;ULNR), and renal function (estimated Cockcroft clearance &#x02265;45&#x000a0;mL/min).</p><p>Patients were excluded if they had a concurrent, uncontrolled medical illness, or previous or current malignant disease.</p><p>Baseline screening evaluations comprised a complete medical examination, including blood cell count and routine blood chemistry, and tumor assessment using radiography. Pre-treatment radiological investigations included a chest X-ray and magnetic resonance imaging (MRI) scans of the upper abdomen (liver) and pelvis. A second MRI scan of the liver and pelvis was performed after completion of the three pemetrexed treatment cycles (as described in the study treatment section below) and before surgery. Staging was performed on pelvic T2-weighted images and a quantitative value of tumor size was measured as the maximal tumor area (mm<sup>2</sup>) on oblique axial T2-weighted images. Post-operative radiological evaluations and tumor outcomes were assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>The trial was conducted with local ethical committee approval and in accordance with Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.</p></sec><sec id="Sec4"><title>Study treatment and [6R]-MTHF dose de-escalation</title><p>Treatment commenced within 4&#x000a0;weeks of the completion of assessments of eligibility. This phase 1 trial utilized a dose de-escalation design to determine the minimum tolerated dose of [6R]-MTHF that is able to abrogate pemetrexed-associated toxicity. In an initial segment of the trial, patients were sequentially assigned to [6R]-MTHF doses of 100, 50, and 10&#x000a0;mg/m<sup>2</sup>, with intrapatient dose de-escalation not permitted. A cohort of six patients was treated at each [6R]-MTHF dose level; however, one patient assigned to receive [6R]-MTHF 10&#x000a0;mg/m<sup>2</sup> was erroneously given a dose of 50&#x000a0;mg/m<sup>2</sup>. Patients were only treated at the next (lower) [6R]-MTHF dose if &#x02264;2 of the 6 (&#x02264;33.3&#x000a0;%) patients reported a dose-limiting toxicity, defined as a grade 3 or 4 drug-related hematologic or gastrointestinal toxicity [<xref ref-type="bibr" rid="CR44">44</xref>] at the current dose. Following a preliminary analysis of safety data, the study protocol was amended to include an additional [6R]-MTHF dose of 500&#x000a0;mg/m<sup>2</sup>.</p><p>[6R]-MTHF was administered as an intravenous (i.v.) bolus injection 1&#x000a0;week prior to the first dose of pemetrexed and then once weekly for 9&#x000a0;weeks; pemetrexed 500&#x000a0;mg/m<sup>2</sup> was administered by i.v. infusion once every 21&#x000a0;days for three cycles. Concomitant medication included vitamin B12 1000&#x000a0;&#x003bc;g by intramuscular injection 1&#x02013;2 weeks prior to the first dose of pemetrexed, and thereafter approximately once every 9&#x000a0;weeks, and two dexamethasone 4&#x000a0;mg oral doses on the day before, the day of, and the day after each administration of pemetrexed. Furthermore, if deemed indicated by the treating physician and the multidisciplinary team at the hospital, patients received radiotherapy for 5 consecutive days (at the earliest on day 17 in cycle 3) as standard care before surgery. Treatment was discontinued in the case of disease progression, unacceptable toxicity, or withdrawal of patient consent.</p></sec><sec id="Sec5"><title>Toxicity assessment</title><p>Adverse events (AEs) were assessed using the Medical Dictionary for Regulatory Activities v11.0 and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 as toxicity grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (life-threatening or disabling), or grade 5 (death related to AE) [<xref ref-type="bibr" rid="CR44">44</xref>]. The relationship of each AE to study drugs and/or procedures was assessed by the investigator. No distinction was made regarding relationship to [6R]-MTHF or pemetrexed unless the AE fulfilled the criteria of a serious AE, which was defined as a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Patients and dose de-escalation schedule</title><p>A total of 24 patients with resectable adenocarcinoma of the rectum (mean age, 63.1&#x000a0;years) were enrolled in the trial and assigned to [6R]-MTHF 500&#x000a0;mg/m<sup>2</sup> (<italic>n</italic>&#x02009;=&#x02009;6), 100&#x000a0;mg/m<sup>2</sup> (<italic>n</italic>&#x02009;=&#x02009;6), 50&#x000a0;mg/m<sup>2</sup> (<italic>n</italic>&#x02009;=&#x02009;7), and 10&#x000a0;mg/m<sup>2</sup> (<italic>n</italic>&#x02009;=&#x02009;5). Baseline demographics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The [6R]-MTHF dose de-escalation schedule is shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics and disease characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">[6R]-MTHF dose, mg/m<sup>2</sup>
</th><th>Overall</th></tr><tr><th/><th>500</th><th>100</th><th>50</th><th>10</th><th/></tr></thead><tbody><tr><td>Patients, n</td><td>6</td><td>6</td><td>7</td><td>5</td><td>24</td></tr><tr><td>Age, years, mean (SD)</td><td>58.17 (8.8)</td><td>62.33 (16.0)</td><td>68.57 (14.3)</td><td>62.40 (11.9)</td><td>63.1 (12.9)</td></tr><tr><td colspan="6">Sex, n (%)</td></tr><tr><td>&#x02003;Female</td><td>4 (66.7)</td><td>3 (50.0)</td><td>2 (28.6)</td><td>1 (20.0)</td><td>10 (41.7)</td></tr><tr><td>&#x02003;Male</td><td>2 (33.3)</td><td>3 (50.0)</td><td>5 (71.4)</td><td>4 (80.0)</td><td>14 (58.3)</td></tr><tr><td>Tumor stage (I/II/III/IV)</td><td>0/2/4/0</td><td>0/1/4/1</td><td>0/1/5/0<sup>a</sup>
</td><td>0/2/3/0</td><td>0/6/16/1</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>MTHF</italic> 5,10-methylene tetrahydrofolate, <italic>SD</italic> standard deviation</p><p>
<sup>a</sup>Staging data is missing for one patient in the 50&#x000a0;mg/m2 group because the patient was withdrawn before final staging could be done</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>[6R]-MTHF dose de-escalation schedule</p></caption><table frame="hsides" rules="groups"><thead><tr><th>[6R]-MTHF dose, mg/m<sup>2</sup>
</th><th>Patients, n</th><th>Doses, n<sup>a</sup>
</th></tr></thead><tbody><tr><td>500</td><td>6</td><td>60</td></tr><tr><td>100</td><td>6</td><td>60</td></tr><tr><td>50</td><td>7</td><td>70</td></tr><tr><td>10</td><td>5</td><td>50</td></tr><tr><td>Total</td><td>24</td><td>240</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviation</italic>: <italic>MTHF</italic> 5,10-methylene tetrahydrofolate</p><p>
<sup>a</sup>All patients received 10 once-weekly doses of [6R]-MTHF, plus pemetrexed 500&#x000a0;mg/m<sup>2</sup> every 21&#x000a0;days, for three cycles</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Toxicity assessments</title><p>Of the 24 enrolled patients, 22 experienced at least one treatment-emergent AE during the study (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). An initial total of 172 treatment-emergent AEs were reported, of which 13 were procedure-related (related to the surgical procedure). After correction for multiple reporting of the same AE code by the same patient, 128 unique treatment-emergent AEs remained. A comprehensive listing of all treatment-emergent AEs is presented in Online Resource <xref rid="MOESM1" ref-type="media">1</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Overview of adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">[6R]-MTHF dose, mg/m<sup>2</sup>
</th><th/></tr><tr><th/><th>500</th><th>100</th><th>50</th><th>10</th><th>Total, n (%)</th></tr></thead><tbody><tr><td>Patients, n</td><td>6</td><td>6</td><td>7</td><td>5</td><td>24</td></tr><tr><td>Patients with &#x02265;1 treatment-emergent AE, n</td><td>4</td><td>6</td><td>7</td><td>5</td><td>22</td></tr><tr><td>Treatment-emergent AEs, n (%)</td><td>24 (18.8)</td><td>16 (12.5)</td><td>52 (40.6)</td><td>36 (28.1)</td><td>128 (100)</td></tr><tr><td>Patients with &#x02265;1 serious AE, n</td><td>1</td><td>0</td><td>3</td><td>1</td><td>5</td></tr><tr><td>Serious AEs, n (%)<sup>a</sup>
</td><td>1 (0.8)</td><td>0</td><td>9 (7.0)</td><td>1 (0.8)</td><td>11 (8.6)</td></tr><tr><td>Patients with &#x02265;1 treatment-related AE, n</td><td>2</td><td>6</td><td>7</td><td>5</td><td>20</td></tr><tr><td>Treatment-related AEs, n (%)</td><td>8 (11.1)</td><td>10 (13.9)</td><td>33 (45.8)</td><td>21 (29.2)</td><td>72 (100)</td></tr><tr><td>Patients discontinued due to AEs, n</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Deaths, n</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></tbody></table><table-wrap-foot><p>All patients received the indicated dose of [6R]-MTHF plus pemetrexed 500&#x000a0;mg/m<sup>2</sup>. Data presented are the number of unique AEs after correction for multiple reporting of of the same AE code by a patient</p><p>
<italic>Abbreviations</italic>: <italic>AE</italic> adverse event, <italic>MTHF</italic> 5,10-methylene tetrahydrofolate</p><p>
<sup>a</sup>Percentages based on the total number of treatment-emergent AEs (<italic>n</italic>&#x02009;=&#x02009;128)</p></table-wrap-foot></table-wrap></p><p>The incidence of treatment-emergent AEs by [6R]-MTHF dose level (500, 100, 50, 10&#x000a0;mg/m<sup>2</sup>) was 18.8&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;24), 12.5&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;16), 40.6&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;52), and 28.1&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;36), respectively (Table <xref rid="Tab3" ref-type="table">3</xref>). The most frequently reported treatment-emergent AEs were fatigue (<italic>n</italic>&#x02009;=&#x02009;18; 14.1&#x000a0;%) and nausea (<italic>n</italic>&#x02009;=&#x02009;11; 8.6&#x000a0;%); only one of each AE was toxicity grade 3 (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Treatment-emergent adverse events with an incidence of &#x02265;5&#x000a0;%</p></caption><table frame="hsides" rules="groups"><thead><tr><th>[6R]-MTHF dose, mg/m<sup>2</sup>
</th><th>500</th><th/><th/><th>100</th><th/><th/><th>50</th><th/><th/><th>10</th><th/><th/><th/><th/></tr><tr><th>Patients, n</th><th colspan="3">6</th><th colspan="3">6</th><th colspan="3">7</th><th colspan="4">5</th><th/></tr><tr><th>Toxicity grade</th><th>1</th><th>2</th><th>3</th><th>1</th><th>2</th><th>3</th><th>1</th><th>2</th><th>3</th><th>1</th><th>2</th><th>3</th><th>4</th><th>Total, n (%)</th></tr></thead><tbody><tr><td colspan="15">Treatment-emergent AEs, n</td></tr><tr><td>&#x02003;All</td><td>17</td><td>5</td><td>2</td><td>14</td><td>2</td><td/><td>37</td><td>10</td><td>5</td><td>26</td><td>8</td><td>1</td><td>1</td><td>128 (100)</td></tr><tr><td>&#x02003;Fatigue</td><td>2</td><td/><td/><td>4</td><td/><td/><td>5</td><td>1</td><td>1</td><td>4</td><td>1</td><td/><td/><td>18 (14.1)</td></tr><tr><td>&#x02003;Nausea</td><td>2</td><td/><td/><td>2</td><td/><td/><td>2</td><td>2</td><td>1</td><td/><td>2</td><td/><td/><td>11 (8.6)</td></tr><tr><td>&#x02003;Pain</td><td>2</td><td/><td/><td>1</td><td/><td/><td/><td>1</td><td>1</td><td/><td>2</td><td/><td/><td>7 (5.5)<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><p>Data presented are the number of unique treatment-emergent AEs after correction for multiple reporting of the same AE code by a patient</p><p>
<italic>Abbreviations</italic>: <italic>AE</italic> adverse event, <italic>MTHF</italic> 5,10-methylene tetrahydrofolate</p><p>
<sup>a</sup>Aggregate incidence of all pain-related AEs, comprising general pain, abdominal pain, headache, lower leg pain, other leg pain, rectal pain, and shoulder pain</p></table-wrap-foot></table-wrap></p><p>A total of 72 treatment-related AEs were reported by 20 patients (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). The incidence of treatment-related AEs by [6R]-MTHF dose level (500, 100, 50, 10&#x000a0;mg/m<sup>2</sup>) was 11.1&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;8), 13.9&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;10), 45.8&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;33), and 29.2&#x000a0;% (<italic>n</italic>&#x02009;=&#x02009;21), respectively (Table <xref rid="Tab3" ref-type="table">3</xref>). The most frequent treatment-related AEs were fatigue (<italic>n</italic>&#x02009;=&#x02009;17; 23.6&#x000a0;%) and nausea (<italic>n</italic>&#x02009;=&#x02009;10; 13.9&#x000a0;%). Two treatment-related AEs were toxicity grade 3 (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Treatment-related adverse events with an incidence of &#x02265;5&#x000a0;%</p></caption><table frame="hsides" rules="groups"><thead><tr><th>[6R]-MTHF dose, mg/m<sup>2</sup>
</th><th>500</th><th/><th/><th>100</th><th/><th/><th>50</th><th/><th/><th>10</th><th/><th/><th/></tr><tr><th>Patients, n</th><th colspan="3">6</th><th colspan="3">6</th><th colspan="3">7</th><th colspan="3">5</th><th/></tr><tr><th>Toxicity grade</th><th>1</th><th>2</th><th>3</th><th>1</th><th>2</th><th>3</th><th>1</th><th>2</th><th>3</th><th>1</th><th>2</th><th>3</th><th>Total, n (%)</th></tr></thead><tbody><tr><td colspan="14">Treatment-related AEs, n</td></tr><tr><td>&#x02003;All</td><td>8</td><td/><td/><td>10</td><td/><td/><td>33</td><td/><td/><td>21</td><td/><td/><td>72 (100)</td></tr><tr><td>&#x02003;Fatigue</td><td>2</td><td/><td/><td>2</td><td>2</td><td/><td>2</td><td>4</td><td/><td>4</td><td>1</td><td/><td>17 (23.6)</td></tr><tr><td>&#x02003;Nausea</td><td>2</td><td/><td/><td>2</td><td/><td/><td>2</td><td>2</td><td/><td/><td>2</td><td/><td>10 (13.9)</td></tr><tr><td>&#x02003;Diarrhea</td><td/><td/><td/><td/><td/><td/><td>2</td><td/><td>1</td><td/><td>1</td><td>1</td><td>5 (6.9)</td></tr></tbody></table><table-wrap-foot><p>Data presented are the number of unique treatment-related AEs after correction for multiple reporting of the same AE code by a patient</p><p>No distinction was made regarding relationship to [6R]-MTHF or pemetrexed unless AEs were assessed as serious AEs</p><p>
<italic>Abbreviations</italic>: <italic>AE</italic> adverse event, <italic>MTHF</italic> 5,10-methylene tetrahydrofolate</p></table-wrap-foot></table-wrap></p><p>Overall, [6R]-MTHF in combination with pemetrexed was associated with a low toxicity profile. No dose-limiting toxicities were reported during the study, and there were no treatment-related grade 4 or 5 AEs. A total of 11 serious AEs (SAEs) were reported; however, none of these were considered to be related to [6R]-MTHF treatment (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). One SAE (fever) was judged to be related to pemetrexed, four were procedure-related (postoperative wound complication, infection, anastomotic leak, abscess [local anastomosis]), and the rest were considered not to be treatment- or procedure-related. Finally, there were no deaths during the study, and no patients discontinued the study due to AEs or SAEs.</p></sec></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>[6R]-MTHF is an enantiomerically pure formulation of the endogenous, biologically active isomer of MTHF [<xref ref-type="bibr" rid="CR46">46</xref>]. Clinical trials are in progress to evaluate the safety and efficacy of [6R]-MTHF as an alternative to leucovorin in potentiating the activity of 5-FU and the antifolates (including pemetrexed, raltitrexed, pralatrexate, and methotrexate) in the treatment of patients with colon and rectal cancer. Leucovorin is a prodrug that requires metabolic conversion to the active cofactor MTHF [<xref ref-type="bibr" rid="CR36">36</xref>], and a corollary of this is that leucovorin administration is associated with considerable intra- and interpatient variability in plasma, tumor, and mucosa MTHF levels [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. Thus, we hypothesized that direct administration of MTHF might provide higher intratumor concentrations of MTHF and, therefore, greater antitumor activity than that seen with leucovorin. Indeed, Wettergren et al. [<xref ref-type="bibr" rid="CR42">42</xref>] recently showed that administration of [6R]-MTHF 200&#x000a0;mg/m<sup>2</sup> resulted in significantly higher MTHF levels in mucosa and tumor tissue in patients with colon cancer, when compared with administration of leucovorin 200&#x000a0;mg/m<sup>2</sup>. However, it has still to be demonstrated that higher intratumor levels of MTHF translate into superior efficacy in terms of tumor response rates and overall survival.</p><p>In the current study, we utilized a dose de-escalation design to identify the optimum dose of [6R]-MTHF to be used in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup>. The rationale behind the de-escalation design was that [6R]-MTHF was acting as a substitute for folic acid, which is routinely given (together with vitamin B12) to patients receiving pemetrexed in order to minimize the risk of severe toxicity [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. Therefore, a key objective was to identify the minimum tolerated dose of [6R]-MTHF that can be used in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup>. Although there were no dose-limiting toxicities at any of the four [6R]-MTHF dose levels, the incidence of treatment-related AEs was markedly lower at the two higher [6R]-MTHF doses (500&#x000a0;mg/m<sup>2</sup>, 11.1&#x000a0;%; 100&#x000a0;mg/m<sup>2</sup>, 13.9&#x000a0;%) than at the two lower doses (50&#x000a0;mg/m<sup>2</sup>, 45.8&#x000a0;%, 10&#x000a0;mg/m<sup>2</sup>, 29.2&#x000a0;%), suggesting that [6R]-MTHF was able to modulate the toxicity of pemetrexed in a dose-dependent manner. Given that the incidence of treatment-related AEs was similar at [6R]-MTHF 500 and 100&#x000a0;mg/m<sup>2</sup>, the minimum tolerated [6R]-MTHF dose was estimated to be 100&#x000a0;mg/m<sup>2</sup> once weekly.</p><p>The most frequent treatment-related AEs were grade 1 fatigue, nausea, and diarrhea, which are common side effects of pemetrexed therapy [<xref ref-type="bibr" rid="CR54">54</xref>]. In contrast to previous trials of pemetrexed in patients with colorectal cancer, none of the patients in the current study reported instances of grade 3/4 neutropenia [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. However, this was a phase 1 study, and larger phase 2/3 studies will provide a more rigorous evaluation of the safety and tolerability of [6R]-MTHF plus pemetrexed combination therapy. With regard to SAEs, none were considered to be related to [6R]-MTHF, corroborating the toxicity findings of Wettergren et al. [<xref ref-type="bibr" rid="CR42">42</xref>], who reported that no AEs/SAEs were related to [6R]-MTHF treatment.</p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusions</title><p>In this phase 1 dose de-escalation trial, [6R]-MTHF doses ranging from 500&#x000a0;mg/m<sup>2</sup> down to 10&#x000a0;mg/m<sup>2</sup>, in combination with pemetrexed 500&#x000a0;mg/m<sup>2</sup>, showed a low toxicity profile in patients with resectable rectal cancer. The estimated minimum tolerated dose of [6R]-MTHF was 100&#x000a0;mg/m<sup>2</sup> once weekly. Phase 2 studies are in progress to further assess the safety, tolerability, and efficacy of [6R]-MTHF as a component of systemic chemotherapy in the management of colon and rectal cancer.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec11"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10637_2015_272_MOESM1_ESM.docx"><label>Online Resource 1</label><caption><p>(DOCX 48 kb)</p></caption></media></supplementary-material></sec></sec></body><back><ack><title>Compliance with ethical standards</title><sec id="FPar1"><title>Ethical approval</title><p>All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p></sec><sec id="FPar2"><title>Informed consent</title><p>Informed consent was obtained from all participants included in the study.</p></sec><sec id="FPar3"><title>Funding</title><p>Isofol Medical AB, Gothenburg, Sweden, sponsored this study.</p></sec><sec id="FPar4"><title>Conflict of interest</title><p>B. Gustavsson is a Director of Isofol Medical AB. F. Gibson is an employee of PharmaGenesis London, UK, which received payment from Isofol Medical AB.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Ervik</surname><given-names>M</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Rebelo</surname><given-names>M</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><source>GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11</source><year>2013</year><publisher-loc>Lyon</publisher-loc><publisher-name>International Agency for Research on Cancer</publisher-name></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><issue>2</issue><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Bouvier</surname><given-names>AM</given-names></name><name><surname>Foschi</surname><given-names>R</given-names></name><name><surname>Hackl</surname><given-names>M</given-names></name><name><surname>Larsen</surname><given-names>IK</given-names></name><name><surname>Lemmens</surname><given-names>V</given-names></name><name><surname>Mangone</surname><given-names>L</given-names></name><name><surname>Francisci</surname><given-names>S</given-names></name></person-group><article-title>Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study</article-title><source>Int J Cancer</source><year>2012</year><volume>131</volume><issue>7</issue><fpage>1649</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1002/ijc.26192</pub-id><pub-id pub-id-type="pmid">21607946</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamos</surname><given-names>MJ</given-names></name><name><surname>Murrell</surname><given-names>Z</given-names></name></person-group><article-title>Management of early rectal T1 and T2 cancers</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>22 Pt 2</issue><fpage>6885</fpage><lpage>6889</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1150</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">(1990) Adjuvant therapy for patients with colon and rectum cancer. Consens Statement 8(4):1&#x02013;25</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name><name><surname>Rockette</surname><given-names>H</given-names></name><name><surname>Redmond</surname><given-names>C</given-names></name><name><surname>Deutsch</surname><given-names>M</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Fisher</surname><given-names>ER</given-names></name><name><surname>Caplan</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>H</given-names></name><etal/></person-group><article-title>Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01</article-title><source>J Natl Cancer Inst</source><year>1988</year><volume>80</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1093/jnci/80.1.21</pub-id><pub-id pub-id-type="pmid">3276900</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglass</surname><given-names>HO</given-names><suffix>Jr</suffix></name><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name><name><surname>Thomas</surname><given-names>PR</given-names></name><name><surname>Lindblad</surname><given-names>AS</given-names></name><name><surname>Mittleman</surname><given-names>A</given-names></name><name><surname>Stablein</surname><given-names>DM</given-names></name><name><surname>Bruckner</surname><given-names>HW</given-names></name></person-group><article-title>Survival after postoperative combination treatment of rectal cancer</article-title><source>N Engl J Med</source><year>1986</year><volume>315</volume><issue>20</issue><fpage>1294</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1056/NEJM198611133152014</pub-id><pub-id pub-id-type="pmid">3773947</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krook</surname><given-names>JE</given-names></name><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Gunderson</surname><given-names>LL</given-names></name><name><surname>Wieand</surname><given-names>HS</given-names></name><name><surname>Collins</surname><given-names>RT</given-names></name><name><surname>Beart</surname><given-names>RW</given-names></name><name><surname>Kubista</surname><given-names>TP</given-names></name><name><surname>Poon</surname><given-names>MA</given-names></name><name><surname>Meyers</surname><given-names>WC</given-names></name><name><surname>Mailliard</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Effective surgical adjuvant therapy for high-risk rectal carcinoma</article-title><source>N Engl J Med</source><year>1991</year><volume>324</volume><issue>11</issue><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1056/NEJM199103143241101</pub-id><pub-id pub-id-type="pmid">1997835</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heald</surname><given-names>RJ</given-names></name><name><surname>Ryall</surname><given-names>RD</given-names></name></person-group><article-title>Recurrence and survival after total mesorectal excision for rectal cancer</article-title><source>Lancet</source><year>1986</year><volume>1</volume><issue>8496</issue><fpage>1479</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(86)91510-2</pub-id><pub-id pub-id-type="pmid">2425199</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enker</surname><given-names>WE</given-names></name><name><surname>Thaler</surname><given-names>HT</given-names></name><name><surname>Cranor</surname><given-names>ML</given-names></name><name><surname>Polyak</surname><given-names>T</given-names></name></person-group><article-title>Total mesorectal excision in the operative treatment of carcinoma of the rectum</article-title><source>J Am Coll Surg</source><year>1995</year><volume>181</volume><issue>4</issue><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">7551328</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacFarlane</surname><given-names>JK</given-names></name><name><surname>Ryall</surname><given-names>RD</given-names></name><name><surname>Heald</surname><given-names>RJ</given-names></name></person-group><article-title>Mesorectal excision for rectal cancer</article-title><source>Lancet</source><year>1993</year><volume>341</volume><issue>8843</issue><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90207-W</pub-id><pub-id pub-id-type="pmid">8094488</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hainsworth</surname><given-names>PJ</given-names></name><name><surname>Egan</surname><given-names>MJ</given-names></name><name><surname>Cunliffe</surname><given-names>WJ</given-names></name></person-group><article-title>Evaluation of a policy of total mesorectal excision for rectal and rectosigmoid cancers</article-title><source>Br J Surg</source><year>1997</year><volume>84</volume><issue>5</issue><fpage>652</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1002/bjs.1800840519</pub-id><pub-id pub-id-type="pmid">9171754</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Yoon</surname><given-names>SM</given-names></name><name><surname>Yu</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name></person-group><article-title>Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer</article-title><source>Cancer</source><year>2011</year><volume>117</volume><issue>16</issue><fpage>3703</fpage><lpage>3712</lpage><pub-id pub-id-type="doi">10.1002/cncr.25943</pub-id><pub-id pub-id-type="pmid">21328328</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>MS</given-names></name><name><surname>Colangelo</surname><given-names>LH</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>MJ</given-names></name><name><surname>Yothers</surname><given-names>G</given-names></name><name><surname>Deutsch</surname><given-names>M</given-names></name><name><surname>Allegra</surname><given-names>CJ</given-names></name><name><surname>Kahlenberg</surname><given-names>MS</given-names></name><name><surname>Baez-Diaz</surname><given-names>L</given-names></name><name><surname>Ursiny</surname><given-names>CS</given-names></name><name><surname>Petrelli</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>31</issue><fpage>5124</fpage><lpage>5130</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.0467</pub-id><pub-id pub-id-type="pmid">19770376</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>R</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Hohenberger</surname><given-names>W</given-names></name><name><surname>Rodel</surname><given-names>C</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name><name><surname>Martus</surname><given-names>P</given-names></name><name><surname>Tschmelitsch</surname><given-names>J</given-names></name><name><surname>Hager</surname><given-names>E</given-names></name><name><surname>Hess</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Preoperative versus postoperative chemoradiotherapy for rectal cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>17</issue><fpage>1731</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040694</pub-id><pub-id pub-id-type="pmid">15496622</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>R</given-names></name><name><surname>Liersch</surname><given-names>T</given-names></name><name><surname>Merkel</surname><given-names>S</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name><name><surname>Hohenberger</surname><given-names>W</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Raab</surname><given-names>HR</given-names></name><name><surname>Villanueva</surname><given-names>MT</given-names></name><name><surname>Witzigmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>16</issue><fpage>1926</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.40.1836</pub-id><pub-id pub-id-type="pmid">22529255</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnetain</surname><given-names>F</given-names></name><name><surname>Bosset</surname><given-names>JF</given-names></name><name><surname>Gerard</surname><given-names>JP</given-names></name><name><surname>Calais</surname><given-names>G</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Mineur</surname><given-names>L</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Maingon</surname><given-names>P</given-names></name><name><surname>Chapet</surname><given-names>O</given-names></name><name><surname>Radosevic-Jelic</surname><given-names>L</given-names></name><etal/></person-group><article-title>What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><issue>12</issue><fpage>1781</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2012.03.016</pub-id><pub-id pub-id-type="pmid">22507892</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Caluwe</surname><given-names>L</given-names></name><name><surname>Van Nieuwenhove</surname><given-names>Y</given-names></name><name><surname>Ceelen</surname><given-names>WP</given-names></name></person-group><article-title>Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>2</volume><fpage>CD006041</fpage><pub-id pub-id-type="pmid">23450565</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceelen</surname><given-names>WP</given-names></name><name><surname>Van Nieuwenhove</surname><given-names>Y</given-names></name><name><surname>Fierens</surname><given-names>K</given-names></name></person-group><article-title>Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>1</volume><fpage>CD006041</fpage><pub-id pub-id-type="pmid">19160264</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosset</surname><given-names>JF</given-names></name><name><surname>Collette</surname><given-names>L</given-names></name><name><surname>Calais</surname><given-names>G</given-names></name><name><surname>Mineur</surname><given-names>L</given-names></name><name><surname>Maingon</surname><given-names>P</given-names></name><name><surname>Radosevic-Jelic</surname><given-names>L</given-names></name><name><surname>Daban</surname><given-names>A</given-names></name><name><surname>Bardet</surname><given-names>E</given-names></name><name><surname>Beny</surname><given-names>A</given-names></name><name><surname>Ollier</surname><given-names>JC</given-names></name></person-group><article-title>Chemotherapy with preoperative radiotherapy in rectal cancer</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>11</issue><fpage>1114</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa060829</pub-id><pub-id pub-id-type="pmid">16971718</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>JP</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Chapet</surname><given-names>O</given-names></name><name><surname>Closon-Dejardin</surname><given-names>MT</given-names></name><name><surname>Untereiner</surname><given-names>M</given-names></name><name><surname>Leduc</surname><given-names>B</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Maurel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>28</issue><fpage>4620</fpage><lpage>4625</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.06.7629</pub-id><pub-id pub-id-type="pmid">17008704</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engstrom</surname><given-names>PF</given-names></name><name><surname>Arnoletti</surname><given-names>JP</given-names></name><name><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Choti</surname><given-names>MA</given-names></name><name><surname>Cooper</surname><given-names>HS</given-names></name><name><surname>Covey</surname><given-names>A</given-names></name><name><surname>Dilawari</surname><given-names>RA</given-names></name><name><surname>Early</surname><given-names>DS</given-names></name><name><surname>Enzinger</surname><given-names>PC</given-names></name><etal/></person-group><article-title>NCCN clinical practice guidelines in oncology: colon cancer</article-title><source>J Natl Compr Canc Netw</source><year>2009</year><volume>7</volume><issue>8</issue><fpage>778</fpage><lpage>831</lpage><pub-id pub-id-type="pmid">19755046</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Tiret</surname><given-names>E</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name></person-group><article-title>Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><issue>Suppl 6</issue><fpage>vi81</fpage><lpage>vi88</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt240</pub-id><pub-id pub-id-type="pmid">24078665</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klautke</surname><given-names>G</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name></person-group><article-title>Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review</article-title><source>Int J Colorectal Dis</source><year>2007</year><volume>22</volume><issue>5</issue><fpage>457</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1007/s00384-006-0204-8</pub-id><pub-id pub-id-type="pmid">17072624</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>LK</given-names></name><name><surname>Bekaii-Saab</surname><given-names>T</given-names></name></person-group><article-title>Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin</article-title><source>J Natl Compr Canc Netw</source><year>2013</year><volume>11</volume><issue>3</issue><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">23486456</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Laskin</surname><given-names>JD</given-names></name><name><surname>Hakala</surname><given-names>MT</given-names></name></person-group><article-title>Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil</article-title><source>Cancer Res</source><year>1981</year><volume>41</volume><issue>9 Pt 1</issue><fpage>3288</fpage><lpage>3295</lpage><pub-id pub-id-type="pmid">6973389</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houghton</surname><given-names>JA</given-names></name><name><surname>Maroda</surname><given-names>SJ</given-names><suffix>Jr</suffix></name><name><surname>Phillips</surname><given-names>JO</given-names></name><name><surname>Houghton</surname><given-names>PJ</given-names></name></person-group><article-title>Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice</article-title><source>Cancer Res</source><year>1981</year><volume>41</volume><issue>1</issue><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">7448754</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyomarsi</surname><given-names>K</given-names></name><name><surname>Moran</surname><given-names>RG</given-names></name></person-group><article-title>Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells</article-title><source>Cancer Res</source><year>1986</year><volume>46</volume><issue>10</issue><fpage>5229</fpage><lpage>5235</lpage><pub-id pub-id-type="pmid">2944577</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustum</surname><given-names>YM</given-names></name><name><surname>Trave</surname><given-names>F</given-names></name><name><surname>Zakrzewski</surname><given-names>SF</given-names></name><name><surname>Petrelli</surname><given-names>N</given-names></name><name><surname>Herrera</surname><given-names>L</given-names></name><name><surname>Mittelman</surname><given-names>A</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Creaven</surname><given-names>PJ</given-names></name></person-group><article-title>Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin</article-title><source>NCI Monogr</source><year>1987</year><volume>5</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">2448653</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullman</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>DW</given-names><suffix>Jr</suffix></name><name><surname>Santi</surname><given-names>DV</given-names></name></person-group><article-title>Cytotoxicity of 5-fluoro-2&#x02032;-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate</article-title><source>Proc Natl Acad Sci U S A</source><year>1978</year><volume>75</volume><issue>2</issue><fpage>980</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1073/pnas.75.2.980</pub-id><pub-id pub-id-type="pmid">147465</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">(1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet 345(8955):939&#x02013;944</mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thirion</surname><given-names>P</given-names></name><name><surname>Michiels</surname><given-names>S</given-names></name><name><surname>Pignon</surname><given-names>JP</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Braud</surname><given-names>AC</given-names></name><name><surname>Carlson</surname><given-names>RW</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>M</given-names></name><name><surname>Sargent</surname><given-names>P</given-names></name><name><surname>Piedbois</surname><given-names>P</given-names></name></person-group><article-title>Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>18</issue><fpage>3766</fpage><lpage>3775</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.03.104</pub-id><pub-id pub-id-type="pmid">15365073</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danenberg</surname><given-names>PV</given-names></name></person-group><article-title>Thymidylate synthetase - a target enzyme in cancer chemotherapy</article-title><source>Biochim Biophys Acta</source><year>1977</year><volume>473</volume><issue>2</issue><fpage>73</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">145246</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santi</surname><given-names>DV</given-names></name><name><surname>McHenry</surname><given-names>CS</given-names></name><name><surname>Sommer</surname><given-names>H</given-names></name></person-group><article-title>Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate</article-title><source>Biochemistry</source><year>1974</year><volume>13</volume><issue>3</issue><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1021/bi00700a012</pub-id><pub-id pub-id-type="pmid">4203910</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Wilt</surname><given-names>CL</given-names></name><name><surname>Pinedo</surname><given-names>HM</given-names></name><name><surname>de Jong</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>GJ</given-names></name></person-group><article-title>Effect of folate diastereoisomers on the binding of 5-fluoro-2&#x02032;-deoxyuridine-5&#x02032;-monophosphate to thymidylate synthase</article-title><source>Biochem Pharmacol</source><year>1993</year><volume>45</volume><issue>5</issue><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(93)90267-Z</pub-id><pub-id pub-id-type="pmid">8461049</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boarman</surname><given-names>DM</given-names></name><name><surname>Allegra</surname><given-names>CJ</given-names></name></person-group><article-title>Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><issue>1</issue><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">1370075</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>G</given-names></name><name><surname>Hafstrom</surname><given-names>LO</given-names></name><name><surname>Spears</surname><given-names>CP</given-names></name><name><surname>Gustavsson</surname><given-names>B</given-names></name><name><surname>Larsson</surname><given-names>PA</given-names></name></person-group><article-title>5-fluorouracil (5-FU) and 5,10-methylene tetrahydrofolate (5,10-CH2FH4) as adjuvant therapy in an experimental rodent colon carcinoma model</article-title><source>Anticancer Res</source><year>1997</year><volume>17</volume><issue>5A</issue><fpage>3671</fpage><lpage>3674</lpage><pub-id pub-id-type="pmid">9413221</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochster</surname><given-names>H</given-names></name></person-group><article-title>The role of pemetrexed in the treatment of colorectal cancer</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><issue>6 Suppl 18</issue><fpage>54</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1053/sonc.2002.37473</pub-id><pub-id pub-id-type="pmid">12571812</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underhill</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Gorbounova</surname><given-names>VA</given-names></name><name><surname>Biakhov</surname><given-names>MY</given-names></name><name><surname>Bazin</surname><given-names>IS</given-names></name><name><surname>Granov</surname><given-names>DA</given-names></name><name><surname>Hossain</surname><given-names>AM</given-names></name><name><surname>Blatter</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name></person-group><article-title>A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer</article-title><source>Oncology</source><year>2007</year><volume>73</volume><issue>1-2</issue><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1159/000120626</pub-id><pub-id pub-id-type="pmid">18334829</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derwinger</surname><given-names>K</given-names></name><name><surname>Kodeda</surname><given-names>K</given-names></name><name><surname>Swartling</surname><given-names>T</given-names></name><name><surname>Kalebo</surname><given-names>P</given-names></name><name><surname>Carlsson</surname><given-names>G</given-names></name><name><surname>Gustavsson</surname><given-names>B</given-names></name></person-group><article-title>A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer</article-title><source>Eur J Surg Oncol</source><year>2011</year><volume>37</volume><issue>7</issue><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2011.04.003</pub-id><pub-id pub-id-type="pmid">21550200</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Isofol Medical AB: Modufolin&#x000ae;. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.isofolmedical.se/modufolin.aspx">http://www.isofolmedical.se/modufolin.aspx</ext-link>. Accessed 24 Nov 2014</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wettergren</surname><given-names>Y</given-names></name><name><surname>Taflin</surname><given-names>H</given-names></name><name><surname>Odin</surname><given-names>E</given-names></name><name><surname>Kodeda</surname><given-names>K</given-names></name><name><surname>Derwinger</surname><given-names>K</given-names></name></person-group><article-title>A pharmacokinetic and pharmacodynamic investigation of Modufolin(R) compared to Isovorin(R) after single dose intravenous administration to patients with colon cancer: a randomized study</article-title><source>Cancer Chemother Pharmacol</source><year>2015</year><volume>75</volume><issue>1</issue><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2611-9</pub-id><pub-id pub-id-type="pmid">25342290</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Sargent</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>R</given-names></name><name><surname>Dancey</surname><given-names>J</given-names></name><name><surname>Arbuck</surname><given-names>S</given-names></name><name><surname>Gwyther</surname><given-names>S</given-names></name><name><surname>Mooney</surname><given-names>M</given-names></name><etal/></person-group><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><issue>2</issue><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">U.S. Department of Health And Human Services: Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Available at: <ext-link ext-link-type="uri" xlink:href="http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf">http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</ext-link>. Accessed 24 Nov 2014</mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">U.S. Food and Drug Administration: Code of Federal Regulations (21CFR312.32). Available at: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32</ext-link>. Accessed 24 Nov 2014</mixed-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baggott</surname><given-names>JE</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name></person-group><article-title>Bioactivity of orally administered unnatural isomers, [6R]-5-formyltetrahydrofolate and [6S]-5,10-methenyltetrahydrofolate, in humans</article-title><source>Biochim Biophys Acta</source><year>1999</year><volume>1472</volume><issue>1-2</issue><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/S0304-4165(99)00135-X</pub-id><pub-id pub-id-type="pmid">10572954</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straw</surname><given-names>JA</given-names></name><name><surname>Szapary</surname><given-names>D</given-names></name><name><surname>Wynn</surname><given-names>WT</given-names></name></person-group><article-title>Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects</article-title><source>Cancer Res</source><year>1984</year><volume>44</volume><issue>7</issue><fpage>3114</fpage><lpage>3119</lpage><pub-id pub-id-type="pmid">6609768</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilsky</surname><given-names>RL</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration</article-title><source>J Natl Cancer Inst</source><year>1990</year><volume>82</volume><issue>17</issue><fpage>1411</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1093/jnci/82.17.1411</pub-id><pub-id pub-id-type="pmid">2388292</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirsch</surname><given-names>SH</given-names></name><name><surname>Herrmann</surname><given-names>W</given-names></name><name><surname>Eckert</surname><given-names>R</given-names></name><name><surname>Geisel</surname><given-names>J</given-names></name><name><surname>Obeid</surname><given-names>R</given-names></name></person-group><article-title>Factors affecting the distribution of folate forms in the serum of elderly German adults</article-title><source>Eur J Nutr</source><year>2013</year><volume>52</volume><issue>2</issue><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s00394-012-0351-3</pub-id><pub-id pub-id-type="pmid">22527285</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taflin</surname><given-names>H</given-names></name><name><surname>Wettergren</surname><given-names>Y</given-names></name><name><surname>Odin</surname><given-names>E</given-names></name><name><surname>Derwinger</surname><given-names>K</given-names></name></person-group><article-title>Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages</article-title><source>Cancer Chemother Pharmacol</source><year>2014</year><volume>74</volume><issue>6</issue><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2591-9</pub-id><pub-id pub-id-type="pmid">25238909</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmanouilides</surname><given-names>C</given-names></name><name><surname>Yermetaki</surname><given-names>T</given-names></name><name><surname>Serpanou</surname><given-names>A</given-names></name><name><surname>Sapountzi</surname><given-names>E</given-names></name><name><surname>Mantziari</surname><given-names>P</given-names></name><name><surname>Titopoulos</surname><given-names>I</given-names></name><name><surname>Filippou</surname><given-names>D</given-names></name></person-group><article-title>Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer</article-title><source>Hematol Oncol Stem Cell Ther</source><year>2010</year><volume>3</volume><issue>1</issue><fpage>34</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/S1658-3876(10)50054-2</pub-id><pub-id pub-id-type="pmid">20231811</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takimoto</surname><given-names>CH</given-names></name><name><surname>Hammond-Thelin</surname><given-names>LA</given-names></name><name><surname>Latz</surname><given-names>JE</given-names></name><name><surname>Forero</surname><given-names>L</given-names></name><name><surname>Beeram</surname><given-names>M</given-names></name><name><surname>Forouzesh</surname><given-names>B</given-names></name><name><surname>de Bono</surname><given-names>J</given-names></name><name><surname>Tolcher</surname><given-names>AW</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><name><surname>Monroe</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>9</issue><fpage>2675</fpage><lpage>2683</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2393</pub-id><pub-id pub-id-type="pmid">17473199</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>TY</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><name><surname>Hsu</surname><given-names>SL</given-names></name><name><surname>Huang</surname><given-names>YR</given-names></name><name><surname>Chiu</surname><given-names>LY</given-names></name><name><surname>Sheu</surname><given-names>GT</given-names></name></person-group><article-title>Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells</article-title><source>Biomed Res Int</source><year>2013</year><volume>2013</volume><fpage>389046</fpage><pub-id pub-id-type="pmid">23984356</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">European Medicines Agency (2009) Summary of product Characteristics. Pemetrexed (Alimta&#x000ae;). <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdf</ext-link>. Accessed July 2015</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Pemetrexed in advanced colorectal cancer</article-title><source>Oncology (Williston Park)</source><year>2004</year><volume>18</volume><issue>13 Suppl 8</issue><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15655939</pub-id></element-citation></ref></ref-list></back></article>